Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency

NCT01420627 is registered in ClinicalTrials.gov with Leadiant Biosciences, Inc. as lead sponsor.

NCT NCT01420627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01420627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency
Lead sponsor
Leadiant Biosciences, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 24, 2014
Completion date
May 29, 2019
Enrollment
7 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ada-scid, adenosine deaminase deficiency, severe combined immunodeficiency